A federal judge has dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk over access to compounded versions of their weight loss drugs. The ruling removes one legal challenge for both companies as they continue to compete for dominance in the obesity drug market. For patients and employers, this news arrives alongside other shifts in how GLP-1 drugs are covered, marketed, and even inspiring new products. Together, these stories show how far the GLP-1 business has grown beyond the medicines themselves.
The lawsuit accused Lilly and Novo Nordisk of illegally blocking access to customized, compounded versions of their weight loss drugs. A U.S. federal judge sided with the pharmaceutical companies and dismissed the case. This outcome matters for patients who have relied on compounded alternatives, since it signals that legal efforts to force broader access through the courts have not succeeded so far. Compound drug makers may pursue other avenues, but for now, Lilly and Novo Nordisk retain firmer control over how their branded GLP-1 products reach the market.
Lilly's recent earnings show it pulling further ahead in the obesity drug race, while Novo Nordisk works to convince investors that its pipeline can still compete. This gap affects more than quarterly results. It shapes which company can invest more heavily in manufacturing, marketing, and future drug development, which in turn affects how quickly new treatments reach patients. Novo Nordisk's challenge is not simply catching up on sales, but rebuilding confidence that its next generation of products can close the distance. Investors will likely watch upcoming trial data and launches closely for signs of that shift.
Javvy, a brand known for its protein coffee powders, is reportedly exploring a sale that could value the company at around $1 billion. The interest stems in part from rising demand for protein-rich products among consumers, including those taking GLP-1 drugs who often need to prioritize protein intake while eating less overall. This shows how the GLP-1 drug market is reshaping consumer habits well beyond pharmacies, opening opportunities for food and beverage brands that serve people managing appetite changes. If the sale goes through, it would mark a significant valuation for a company built around this trend.
Starbucks plans to stop covering GLP-1 drugs for weight loss under its employee health benefits, joining a broader pullback among employers facing rising costs. This decision reflects a real tension for companies offering these benefits, since the drugs are effective but expensive to cover at scale for large workforces. Employees who currently use these benefits for weight loss coverage may need to explore other payment options or discuss alternatives with their prescribing doctor. This shift may prompt other employers to reconsider their own coverage policies if costs continue to climb.
Omnicom has won Novo Nordisk's U.S. media account for Ozempic and Wegovy, a deal valued at $520 million, beating out the incumbent agency WPP. This account covers the advertising and media strategy behind two of the most recognized GLP-1 brand names in the country. The size of the deal reflects how much Novo Nordisk continues to invest in maintaining visibility for these drugs, even as competition from Lilly intensifies. How Omnicom shapes future campaigns may influence public perception of these drugs at a time when coverage debates and market competition are both increasing.
Readers following the GLP-1 drug market should notice how these stories connect. Legal outcomes, earnings reports, and coverage decisions all affect who can access these drugs and at what cost. Anyone currently taking or considering a GLP-1 drug may want to check with their employer about coverage changes and speak with their doctor about affordable options if a benefit like Starbucks employees are seeing gets reduced. The broader market, from beverage brands to advertising accounts, will keep shifting as demand grows, so it is reasonable to expect more changes in the months ahead.
Key details
Lilly and Novo won dismissal of an antitrust suit over compounded GLP-1 drug access.
Lilly widens its obesity drug lead while Novo works to regain investor confidence.
Javvy, a protein coffee brand, may sell for about $1 billion amid GLP-1 demand.
Starbucks will drop GLP-1 coverage for weight loss as employers pull back on rising costs.
Omnicom now handles Novo Nordisk's $520 million U.S. media account for Ozempic and Wegovy.
Sources
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market — CNBC
Protein coffee brand Javvy explores sale, sources say — Reuters
1 Coverage for Weight Loss As Costs Climb — Business Insider
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk — Adweek